NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$80.89
-2.60 (-3.11%)
Close of Nov 06, 2026 · end-of-day data
LMAT 8-K filings, explained
Every material Form 8-K LeMaitre Vascular has filed with the SEC since June 03, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
LeMaitre reported preliminary third-quarter 2026 sales of $68.0 million, up 11% from a year earlier, while diluted EPS fell 14% to $0.65 and operating income fell 13% to $17.7 million. The company kept its full-year 2026 outlook, guiding to sales of $274.8 million to $276.8 million and EPS of $2.77 to $2.82, and declared a $0.25 quarterly dividend. The company also bought certain vascular assets from B. Braun for $19.2 million in October.
Q3 2026 net sales $68.0 million, up 11% (12% organic) from Q3 2025; diluted EPS $0.65 versus $0.75
Q3 operating income $17.7 million versus $20.3 million a year earlier; the prior-year period included a $3.4 million employee retention tax credit benefit
FY 2026 guidance: sales $274.8 million to $276.8 million and EPS $2.77 to $2.82; Q4 EPS guidance $0.70 to $0.75
Quarterly dividend of $0.25 per share payable December 3, 2026, to holders of record on November 19, 2026
LeMaitre Vascular reported preliminary Q2 2026 results with net sales of $70.4 million, up 10% from a year earlier, and operating income of $20.4 million, up 26%. The company also gave guidance: full-year 2026 sales of $274.3 million to $278.3 million and diluted EPS of $2.84 to $2.94, while third-quarter operating income and EPS are guided below last year's levels, which included a one-time employee retention tax credit benefit.
Q2 2026 net sales $70.4 million, up 10%; gross margin 72.1%, up 210 basis points; diluted EPS $0.74, up 23% from $0.60.
Full-year 2026 guidance: sales $274.3 million to $278.3 million; EPS $2.84 to $2.94, midpoint up 15% from 2025 as reported.
Q3 2026 guidance: EPS $0.66 to $0.71 and operating income $17.3 million to $18.8 million, both below Q3 2025 as reported, which included an employee retention tax credit benefit.
Board approved a quarterly dividend of $0.25 per share, payable September 3, 2026, to holders of record on August 20, 2026.
LeMaitre Vascular reported preliminary first-quarter 2026 results, with net sales up 11% to $66.6 million and diluted EPS up 42% to $0.68 from a year earlier. Management said full-year 2026 guidance was increased, now projecting sales of $277 million to $283 million and EPS of $2.93 to $3.08.
Q1 2026 net sales of $66.6 million, up 11% (10% organic) versus Q1 2025; gross margin 72.7%, up 350 basis points
Q1 2026 diluted EPS of $0.68 versus $0.48 in Q1 2025; income from operations of $17.8 million, up 41%
Full-year 2026 guidance: sales of $277 million to $283 million and EPS of $2.93 to $3.08; Q2 2026 sales guidance of $70.5 million to $72.5 million
Quarterly dividend of $0.25 per share, payable June 4, 2026 to holders of record on May 21, 2026
LeMaitre Vascular director Bridget Ross notified the board on April 8, 2026 that she will not stand for re-election at the June 2, 2026 annual meeting, and she will serve until then. The board nominated David B. Roberts for a Class II seat to rebalance board classes; he conditionally resigned his Class I seat, and the board will shrink from eight to seven members. The filing describes these changes as administrative and states no disagreements with the company.
Bridget Ross, Class II director, notified the board on April 8, 2026 of her intent not to stand for re-election
David B. Roberts nominated as Class II director; he notified the board on April 9, 2026 of his conditional resignation as a Class I director
Board size reduced from eight to seven members, effective upon Ross's departure; board to have two Class I, two Class II and three Class III directors
LeMaitre Vascular reported preliminary fourth-quarter 2025 sales of $64.5 million, up 16%, with operating income of $18.8 million, up 47%. The company also guided to 2026 full-year sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01, and raised its quarterly dividend 25% and authorized a $100.0 million share repurchase program.
Q4 2025 diluted EPS was $0.68, up 39% from the prior-year quarter, and gross margin was 71.7%, up 240 basis points.
Full-year 2026 guidance calls for sales of $276 million to $284 million and diluted EPS of $2.81 to $3.01.
On February 19, 2026, the board raised the quarterly dividend 25% to $0.25 per share, payable March 26, 2026, and authorized up to $100.0 million in buybacks through February 18, 2027.
LeMaitre Vascular reported preliminary, unaudited third-quarter 2025 results, with sales up 11% to $61.0 million and GAAP diluted EPS up 54% to $0.75. The results include a non-recurring $3.4 million Employee Retention Tax Credit benefit, and excluding it, adjusted diluted EPS was $0.62, up 27%. Management said it increased its bottom-line guidance, with full-year 2025 GAAP diluted EPS now expected at $2.48 to $2.53.
Q3 2025 net sales $61.0 million, up 11% (12% organic); GAAP diluted EPS $0.75, up 54%
Adjusted diluted EPS $0.62, up 27%, excluding the Employee Retention Tax Credit benefit
Full-year 2025 sales guidance $247 million to $249 million; Q4 2025 sales guidance $61.8 million to $63.8 million
Quarterly dividend of $0.20 per share, payable December 4, 2025, to holders of record on November 20, 2025
LeMaitre Vascular reported preliminary second-quarter 2025 results, with net sales of $64.2 million, up 15%, and diluted earnings per share of $0.60, up 16%. The company raised its full-year 2025 sales and earnings guidance, now projecting sales of $248 million to $254 million and diluted EPS of $2.23 to $2.37. The results are preliminary and unaudited.
Q2 2025 gross margin was 70.0%, up from 68.9% a year earlier, and operating income was $16.1 million, up 12%.
Full-year 2025 guidance: sales of $248 million to $254 million and EPS of $2.23 to $2.37.
Q3 2025 guidance: sales of $61.2 million to $63.2 million and EPS of $0.54 to $0.59.
Board approved a $0.20 per share quarterly dividend, payable September 4, 2025, to holders of record on August 21, 2025.
LeMaitre Vascular reported first-quarter 2025 net sales of $59.9 million, up 12% from a year earlier, and diluted earnings per share of $0.48, up from $0.44. The company raised its full-year 2025 sales guidance to $242 million to $249 million, from a prior $239 million, which gives shareholders a higher revenue outlook.
Q1 2025 net sales $59.9 million, up 12% (13% organic); gross margin 69.2%, up 60 basis points
Diluted EPS $0.48 vs. $0.44 a year earlier; income from operations $12.6 million, up 6%
Full-year 2025 sales guidance $242 million to $249 million, up from prior $239 million; Q2 sales guidance $61.5 million to $63.5 million
Quarterly dividend of $0.20 per share, payable May 29, 2025 to holders of record on May 15, 2025
LeMaitre Vascular reported preliminary fourth-quarter 2024 results, with net sales of $55.7 million, up 14% from a year earlier, and diluted EPS of $0.49 versus $0.38. The company also gave 2025 guidance of $235.4 million to $242.8 million in sales and $2.15 to $2.32 in EPS, and raised its quarterly dividend 25% to $0.20 per share. Sales and earnings growth, plus the dividend increase and a share repurchase authorization of up to $75.0 million, are the main items for shareholders.
Q4 2024 net income was $11.2 million, versus $8.5 million in Q4 2023; operating income was $12.9 million, up 26%.
Gross margin was 69.3%, up from 68.1% in Q4 2023.
2025 full-year sales guidance is $235.4 million to $242.8 million, compared with 2024 sales of $219.9 million.
The quarterly dividend rises to $0.20 per share, payable March 27, 2025; the board authorized up to $75.0 million in buybacks through February 17, 2026.
LeMaitre Vascular agreed on February 7, 2025 to appoint Dorian LeBlanc as Chief Financial Officer and principal financial officer, effective March 10, 2025. LeBlanc most recently served as CFO of LumiraDx Limited, and later as its Chief Operating Officer, and the filing describes his offer letter terms, including base salary, bonus target, equity awards and severance.
Dorian LeBlanc agreed to terms on February 7, 2025 and takes over as CFO effective March 10, 2025.
Starting annual base salary of $565,000, with a discretionary bonus target of $225,000 and an annual equity award of $375,000 vesting over four years.
One-time restricted stock unit award valued at $100,000, vesting over four years.
If terminated without cause on or before March 10, 2028, severance is $100,000; after that date, it is the greater of two weeks of base salary per full year of service or $225,000.
LeMaitre Vascular issued $172.5 million of 2.50% convertible senior notes due 2030 on December 19, 2024, including the full $22.5 million option exercised by the initial purchasers. The company says it will use the net proceeds for working capital and general purposes, which may include acquisitions or investments, and the notes add debt that can convert into common stock at about $119.73 per share.
Notes: $172.5 million principal, 2.50% annual interest, maturing February 1, 2030
Initial conversion price of approximately $119.73 per share (8.3521 shares per $1,000 principal)
Company may settle conversions in cash, shares, or a combination; notes redeemable on or after February 5, 2028 under stated conditions
Notes are unsecured senior obligations under an indenture with U.S. Bank Trust Company, National Association, as trustee
LeMaitre Vascular reported preliminary, unaudited results for the quarter ended September 30, 2024, with net sales of $54.8 million, up 16% from a year earlier, and diluted earnings per share of $0.49, up from $0.33. The company also raised its full-year 2024 guidance, which for sales is $219.0 million to $221.0 million and for EPS is $1.91 to $1.96, giving shareholders a higher outlook for growth and profit.
Q3 2024 net sales were $54.8 million, up from $47.4 million in Q3 2023.
Q3 operating income was $13.1 million, up from $9.2 million, and diluted EPS was $0.49 versus $0.33.
Full-year 2024 sales guidance is $219.0 million to $221.0 million, and EPS guidance is $1.91 to $1.96.
The Board approved a $0.16 per share quarterly dividend, payable December 5, 2024, to holders of record on November 21, 2024.
LeMaitre Vascular said Chief Financial Officer Joseph P. Pellegrino Jr. will retire as an employee effective March 7, 2025, after the anticipated filing of the 2024 Form 10-K, and will remain on the Board of Directors. The company will search for a replacement CFO and expects Pellegrino to take part in the hiring process. The company also reaffirmed its August 1, 2024 financial guidance for Q3 and full-year 2024 as of August 26, 2024.
Pellegrino retires as an employee, including as CFO, effective March 7, 2025
He remains on the Board, serving out his term until June 2027 after being re-elected in June 2024
The company thanks him for 19 years of executive service and will search for a replacement CFO
Guidance from August 1, 2024 for Q3 2024 and Full-Year 2024 was reaffirmed as of August 26, 2024
LeMaitre Vascular reported preliminary second-quarter 2024 results, with sales of $55.8 million, up 11% from a year earlier, and net income of $11.8 million, up 46%. The company raised its full-year 2024 guidance, now projecting sales of $216.8 million to $220.8 million and EPS of $1.82 to $1.91, which shareholders will weigh alongside the company's higher quarterly profitability.
Q2 2024 sales $55.8 million, up 11% (12% organic); diluted EPS $0.52, up 44%
Gross margin 68.9%, up from 64.0% in Q2 2023; operating income $14.4 million, up 52%
Full-year 2024 guidance: sales $216.8 million to $220.8 million; EPS $1.82 to $1.91
Quarterly dividend of $0.16 per share payable August 29, 2024, to holders of record August 15, 2024
At its June 3, 2024 annual meeting, LeMaitre Vascular shareholders re-elected or elected three Class III directors, but Lawrence J. Jasinski received 8,277,096 votes for and 11,308,332 withheld. Under the company's governance guidelines he tendered his resignation, but the board rejected it after considering the Nominating and Corporate Governance Committee's recommendation. Shareholders also approved an amended stock option and incentive plan that authorizes 1,000,000 new shares and extends the plan to June 3, 2034.
Jasinski received fewer votes for than against his election; the board rejected his resignation on June 3, 2024
Amended and restated stock option plan approved with 19,332,353 votes for and 411,532 against, adding 1,000,000 shares and running to June 3, 2034
Advisory say-on-pay vote approved with 19,118,371 votes for and 624,991 against
Grant Thornton LLP ratified as independent auditor for the year ending December 31, 2024 (20,642,552 for, 93,844 against)
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every LeMaitre Vascular filing is on SEC EDGAR ↗. 8-K briefs of other companies →